Expatriates suffering from epilepsy may soon be able to go through new diagnostic processes, paid for by international private medical insurance policies.
Professor Sanjay Sisodiya from UCL Institute of Neurology (Department of Clinical and Experimental Epilepsy) explained he is trying to discover how genetics influence the way in which individuals respond to treatment with antiepileptic drugs (AEDs).
This is through the EpiPGX Consortium, which consists of 15 partners from eight countries.
It recently received almost €6 million though the European Union FP7 programme to look into the role genes play in AEDs.
The knowledge gained through this money could help healthcare professionals choose the best medicines for epileptics, while minimising the likelihood of adverse side effects among individuals, stated Professor Sisodiya, who coordinates the consortium.
Epilepsy might be better understood as a result of this investigation, which could help in the development of new treatments for the condition, he predicted.